Company Introduction

基亞生物科技股份有限公司成立於1999年底，結合台灣生技醫療研發能量、國際臨床開發經驗、與最新的技術商化競爭力，鋪建了完整專利保護的各種專題，基亞將有效地將研發與技術轉化為全球各國法規單位認可的醫療產品。
 
本公司鎖定亞洲重大疾病「肝病」與「癌症」兩大領域的新產品為開發核心。透過過去多年的努力耕耘，基亞生技已逐漸發展成為全方位的生物醫藥集團，其事業已涵蓋了：新藥臨床開發、創新生物醫藥研發平台、分子檢測、細胞培養疫苗科技、學名藥生產行銷等多項事業。
 
基亞生技基亞團隊自期成為亞洲首屈一指的生技標竿企業，立足台灣，透過新事業體擴張與國際併購成為跨國生技醫藥集團，並堅持為人類守護生命與健康之理念，實踐『創新讓生命更美好』的精神
 
Medigen is a biopharmaceutical company focusing on the development of new drugs and cell therapies for cancer treatments. Currently, two cell therapies are well established in Taiwan, Magicell®-NK and Magicell®- GDT. Both have shown enormous abilities to kill a wide spectrum of tumor cells with high cells number and purity. Currently, both cell therapies can be reached for cancer treatment in several hospitals under the Special Art. With the mission of guarding the life and health of human beings, Medigen will continue to make every possible endeavor to develop a full range of cell therapy services for needed populations.

Brief description of main products or services 

Magicell®-NK and Magicell®-GDT are two main cell products of Meigen. Magicell®-NK is a new generation of natural killer cell therapy by using Medigen’s state-of-the-art cell processing technology. Without adding any harmful material or feeder cells, high cell numbers of cells with high purity can be achieved. Most importantly, the cytotoxic activity of Magicell®-NK is also significantly high and shown strong evidence against a wide spectrum of tumor cells including liver, colon, kidney, and lung cancers. From current performance, no adverse effects were observed in multiple cell infusion. The product will be beneficial for both autologous and allogeneic applications for cancer treatment.
 
Magicell®-GDT is a gamma-delta T cell with well-established protective roles against cancers. Through our Japan partner, MEDINET, the product has shown remarkable clinical benefits in patients with various types of cancers at more than 50 medical institutions since 2007. Magicell®-GDT can also be combined with other therapies to improve the clinical responses. Currently, both Magicell®-NK and Magicell®-GDT are produced at Medigen’s cell processing center with GTP certificates and can be reached under the Special Act in Taiwan. Medigen is upholding the vision of “Innovations for a better life” and devoting ourselves to provide quality solutions for cancer patients continuously.